tradingkey.logo

Inotiv Inc

NOTV
查看详细走势图
0.418USD
+0.028+7.26%
收盘 02/06, 16:00美东报价延迟15分钟
14.37M总市值
亏损市盈率 TTM

Inotiv Inc

0.418
+0.028+7.26%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+7.26%

5天

-16.39%

1月

-30.85%

6月

-78.66%

今年开始到现在

-25.58%

1年

-88.08%

查看详细走势图

TradingKey Inotiv Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Inotiv Inc当前公司基本面数据相对稳定,最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名146/392位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.83。中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Inotiv Inc评分

相关信息

行业排名
146 / 392
全市场排名
291 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

Inotiv Inc亮点

亮点风险
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
估值高估
公司最新PE估值-0.20,处于3年历史高位
机构减仓
最新机构持股8.26M股,环比减少32.19%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值79.45K

分析师目标

根据 2 位分析师
买入
评级
4.833
目标均价
+986.14%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Inotiv Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Inotiv Inc简介

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
公司代码NOTV
公司Inotiv Inc
CEOLeasure (Robert W)
网址https://www.inotiv.com/
KeyAI